首页 | 本学科首页   官方微博 | 高级检索  
     


Growth differentiation factor-15 in Takotsubo cardiomyopathy: Diagnostic and prognostic value
Authors:T. Stiermaier  V. AdamsM. Just  S. BlazekS. Desch  G. SchulerH. Thiele  I. Eitel
Affiliation:University of Leipzig-Heart Center, Department of Internal Medicine-Cardiology, Leipzig, Germany
Abstract:

Background

Growth differentiation factor-15 (GDF-15), a stress responsive cytokine, has emerged as a marker of adverse outcome in various cardiovascular diseases. Since GDF-15 has not been evaluated in patients with Takotsubo cardiomyopathy (TTC), the present study sought to investigate the diagnostic and prognostic value in this patient cohort.

Methods

A total of 22 patients presenting with TTC were matched for age and gender with 22 ST-segment elevation myocardial infarction (STEMI) patients. GDF-15 concentrations were measured at admission and 1 day thereafter. The primary clinical endpoint of the TTC cohort was the composite of death, cardiogenic shock, or new congestive heart failure within 6 months.

Results

TTC patients showed significantly higher GDF-15 values on admission compared to patients presenting with STEMI (median 3047 ng/l [interquartile range 2256–7572] versus median 1527 ng/l [interquartile range 1152–2677]; p = 0.002). TTC patients with a biventricular ballooning pattern and patients experiencing major adverse cardiac events during the first 6 months after acute presentation showed significantly higher GDF-15 concentrations on admission (p = 0.008 and p = 0.005, respectively). Biventricular ballooning was identified as a predictor for elevated GDF-15 values on admission (p = 0.03). High GDF-15 levels on admission were the only significant predictor for the combined clinical endpoint in multivariable regression analysis (p = 0.02).

Conclusion

TTC patients showed markedly high, but transient elevation of GDF-15 levels. Biventricular ballooning was associated with particularly high GDF-15 concentrations. Elevated GDF-15 values on admission were a strong predictor of adverse clinical outcome.
Keywords:ACS, acute coronary syndrome   CI, confidence interval   CK, creatine kinase   CMR, cardiovascular magnetic resonance   BNP, B-type natriuretic peptide   GDF-15, growth differentiation factor-15   IQR, interquartile range   LGE, late gadolinium enhancement   LV, left ventricular   MACE, major adverse cardiovascular events   MR-proANP, mid-regional pro-atrial natriuretic peptide   PCI, percutaneous coronary intervention   RNA, ribonucleic acid   RV, right ventricular   STEMI, ST-elevation myocardial infarction   TTC, Takotsubo cardiomyopathy
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号